Comparative Pharmacology
Head-to-head clinical analysis: NEPHROFLOW versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROFLOW versus NEPHROSCAN.
NEPHROFLOW vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical